Commercial lag is one of the most expensive hidden problems in life sciences companies. Learn why commercial success in CGT requires both deal execution and market positioning — and why one commercial hire is often not enough.
In today’s Cell and Gene Therapy market, scientific differentiation alone is no longer enough. Learn why CGT companies must build commercial authority early — and how positioning, visibility, and market trust drive long-term commercial success.
In Cell and Gene Therapy, the biggest risk is not weak science — it is unrealistic budgeting. Learn why CGT companies must build financial buffer, commercialization infrastructure, and scale-up readiness long before first-in-human data.
The science behind Cell and Gene Therapy is advancing rapidly, but commercialization systems are lagging behind. Discover how “Commercial Gravity” prevents breakthrough therapies from reaching patients — and what CGT companies can do to overcome it.